Phase I/II Study of Autologous Tumor Cell Vaccination Using Metronomic Cyclophosphamide, 3-Dimensional Conformal Radiotherapy, Intra/Peri-Tumor Injection of Poly ICLC With Trans-Hepatic Arterial Embolization Followed by Poly ICLC Boosting in Patients With Unresectable, Recurrent, or Metastatic Cancers in the Liver (Hepatoma, Cholangiocarcinoma, Neuroendocrine, Breast, Colon, Gastric, and Esophageal Cancer).

Trial Profile

Phase I/II Study of Autologous Tumor Cell Vaccination Using Metronomic Cyclophosphamide, 3-Dimensional Conformal Radiotherapy, Intra/Peri-Tumor Injection of Poly ICLC With Trans-Hepatic Arterial Embolization Followed by Poly ICLC Boosting in Patients With Unresectable, Recurrent, or Metastatic Cancers in the Liver (Hepatoma, Cholangiocarcinoma, Neuroendocrine, Breast, Colon, Gastric, and Esophageal Cancer).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Aug 2015

At a glance

  • Drugs Poly ICLC (Primary) ; Poly ICLC (Primary) ; Cyclophosphamide
  • Indications Advanced breast cancer; Cholangiocarcinoma; Colon cancer; Gastric cancer; Liver cancer; Liver metastases; Malignant melanoma; Neuroendocrine carcinoma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Jan 2014 Endpoints amended as reported by ClinicalTrials.gov
    • 11 Jan 2014 Planned End Date changed from 1 Oct 2009 to 1 Jul 2014 as reported by ClinicalTrials.gov
    • 30 Jun 2009 New source identified and integrated (New Jersey Cancer Trial Connect).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top